36.6 F
New York
Thursday, April 22, 2021

AstraZeneca [NYSE: AZN] Announces $6 Billion Cancer Drug Deal With Daiichi Sankyo

Must read

Palantir [NYSE: PLTR] Recognized as a Crown Commercial Service supplier

Palantir Technologies Inc. has gained recognition as a supplier on the Crown Commercial Service (CCS) Back Office Software (BOS) RM6194 Framework. This award...

Trevena [NASDAQ: TRVN] Soar on Selection of TRV027in Global COVID-19 Trial

Shares of Trevena, Inc. skyrocketed more than 5 percent during the pre-market trading session of Wednesday. The strong performance of the firm indicated...

InfuSystem Announces Acquisition of OB Healthcare Corporation

InfuSystem Holdings Inc. disclosed Wednesday that it has bought OB Healthcare Corporation. As per the acquisition agreement, the firm has purchased the operating...

IAA [NYSE: IAA] Announces Expansion of Delivery Services in the UK

IAA, Inc. disclosed that its UK-based business unit has decided to expand its vehicle delivery services for its buyers. This expansion decision has...

AstraZeneca PLC announced Monday it has signed a $6 billion deal with Japan’s second-largest pharmaceutical company, Daiichi Sankyo for the making and introduction of new antibody-drug conjugate (ADC).

The new deal inked among two companies for the making of DS-1062, TROP2 directed antibody-drug conjugate (ADC) of Daiichi, and for the new drugs for the treatment of various tumors type. British pharmaceutical company unveiled that the drug is currently in the development stage.

DS-1062 is currently in the making for the treatment of multiple tumors that typically exhibit cell surface glycoprotein TROP2. TROP2 is a transmembrane glycoprotein. It is differently exhibited in many cancers and it is overexpressed in many cancer cells.

TROP2 overexpression leads to the growth and proliferation of cancer cells. It is a promising target for the development process. While DS-1062 is a TROP2 directed ADC.

Shares of AstraZeneca soared 1.14% during the trading of Friday. It has a closing price of $55.80. In the past 52-weeks of trading, its stocks fluctuated between the low of $36.15 and a high of $64.94. AZN has moved up 54.36% from its 52-weeks low and moved down -14.07% from its 52-weeks high.

If we look at its profitability, it has a return on assets of 2.50%, return on investment of 8.30% and return on equity of 12.30%. British giant has a gross margin of 79.60%, a profit margin of 6.00%, and an operating margin of 12.10%. AZN has a market cap of 146.21 billion. If we look at its liquidity, it has a quick ratio of 0.60 and a current ratio of 0.80.

As per the contract, AstraZeneca will pay the upfront payment of $1 billion in staged payment, $350 million is due upon completion, $325 million after 12-months, and a $325 million after 24 months from the effective date of the contract. The British giant will pay $1 billion for the successful regulatory approval and will pay $4 billion for sales-related milestones.

Both the companies will jointly work to make and introduce DS-1062 worldwide except in Japan where Daiichi will maintain exclusive rights. As per the deal, both Daiichi and AstraZeneca will share all the expenses and the profits equally incurred in the development and commercialization of DS-1062.

More articles

Latest article

ICON [NASDAQ: ICLR] Secures Multiple Categories in 2021 CRO Leadership Awards

ICON Public Limited Company has disclosed that it has won multiple categories in the annual CRO Leadership Awards. This is another greatest achievement...

Equinox Announces Sale of Pilar Gold Mine

Equinox Gold Corp. revealed Monday that it has decided to sell its Pilar Gold Mine in Brazil to Pilar Gold Inc. The firm...

OpGen [NASDAQ: OPGN] Announces Strategic Collaboration New York State Department of Health

OpGen, Inc. revealed that it has entered into a strategic collaboration deal with the New York State Department of Health. The focus of...

Why Mer Telemanagement [NASDAQ: MTSL] Skyrocketed on Friday?

Shares of Mer Telemanagement Solutions Ltd skyrocketed during the trading session of Friday. The strong performance of the firm has indicated the positive...

Largo Resources Gets Approval for Listing on Nasdaq Stock Exchange

Largo Resources disclosed that it has finally obtained authorization from Nasdaq Stock Market LLC. As per the approval, the firm will now eligible to...

Aurora Mobile [NASDAQ: JG] Inks Agreement with Wanda Film

Aurora Mobile Limited disclosed Thursday that it has inked an agreement with Wanda Film Holding Co Ltd. Since its inception, Aurora Mobile has...

Brady [NYSE: BRC] Commence Tender Offer to Buy Nordic ID Oyj

Brady Corporation has inked an agreement with Nordic ID for its acquisition. The firm has commenced the tender offering to buy all the...

Cinedigm [NASDAQ: CIDM] Achieve Record Subscription and Ad-Supported User Growth Milestones

Shares of Cinedigm Corp. skyrocketed 19.30% after the firm reported the update about the subscription. The firm has achieved the best ever achievement...